A mathematical estimation for quantified calcium supplementation during intermittent hemodialysis using regional citrate anticoagulation.


Journal

Artificial organs
ISSN: 1525-1594
Titre abrégé: Artif Organs
Pays: United States
ID NLM: 7802778

Informations de publication

Date de publication:
Jun 2022
Historique:
revised: 21 12 2021
received: 19 07 2021
accepted: 23 12 2021
pubmed: 4 1 2022
medline: 21 5 2022
entrez: 3 1 2022
Statut: ppublish

Résumé

Regional citrate anticoagulation has been recommended as an alternative of anticoagulation for patients at high risk of bleeding undergoing intermittent hemodialysis. Precise calcium supplementation is important for the safety of regional citrate anticoagulation. In this study, we aimed to develop a possible method to optimize calcium supplementation for regional citrate anticoagulation in intermittent hemodialysis. The investigation consisted of a pilot study and a validation study. 18 patients undergoing intermittent hemodialysis anticoagulated by citrate, and six types of filters were included in the pilot study. The ionized calcium levels were monitored and maintained in the targeted range. Calcium-free dialysate was used in the study. After linear regression analysis of the clearance of non-protein bound calcium and calculating the ratio of the non-protein bound calcium concentration to total calcium concentration, we developed a mathematical model for estimation of extracorporeal circuit calcium removal. Another 8 maintenance hemodialysis patients (12 sessions) were enrolled in the validation study to validate the new version of the calcium supplementation approach. In the pilot study, positive correlations were found between the clearance of non-protein bound calcium and the hematocrit-adjusted clearance of creatinine and phosphate given in the dialyzer leaflet (R We developed a possible method to quantify calcium supplementation for intermittent hemodialysis anticoagulated by citrate which may help to avoid negative calcium balance and reduce the incidence of complications.

Sections du résumé

BACKGROUND BACKGROUND
Regional citrate anticoagulation has been recommended as an alternative of anticoagulation for patients at high risk of bleeding undergoing intermittent hemodialysis. Precise calcium supplementation is important for the safety of regional citrate anticoagulation. In this study, we aimed to develop a possible method to optimize calcium supplementation for regional citrate anticoagulation in intermittent hemodialysis.
METHODS METHODS
The investigation consisted of a pilot study and a validation study. 18 patients undergoing intermittent hemodialysis anticoagulated by citrate, and six types of filters were included in the pilot study. The ionized calcium levels were monitored and maintained in the targeted range. Calcium-free dialysate was used in the study. After linear regression analysis of the clearance of non-protein bound calcium and calculating the ratio of the non-protein bound calcium concentration to total calcium concentration, we developed a mathematical model for estimation of extracorporeal circuit calcium removal. Another 8 maintenance hemodialysis patients (12 sessions) were enrolled in the validation study to validate the new version of the calcium supplementation approach.
RESULTS RESULTS
In the pilot study, positive correlations were found between the clearance of non-protein bound calcium and the hematocrit-adjusted clearance of creatinine and phosphate given in the dialyzer leaflet (R
CONCLUSIONS CONCLUSIONS
We developed a possible method to quantify calcium supplementation for intermittent hemodialysis anticoagulated by citrate which may help to avoid negative calcium balance and reduce the incidence of complications.

Identifiants

pubmed: 34978734
doi: 10.1111/aor.14164
doi:

Substances chimiques

Anticoagulants 0
Citrates 0
Citric Acid 2968PHW8QP
Calcium SY7Q814VUP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1122-1131

Subventions

Organisme : Shanghai Ninth People's Hospital Clinical Research Program
ID : JYLJ007
Organisme : Science & Technology Innovation fund of Shanghai Ninth People's Hospital
ID : CK2019010
Organisme : National Natural Science Foundation of China
ID : 81470990
Organisme : National Natural Science Foundation of China
ID : 81870462
Organisme : Science and Technology Commission of Shanghai Municipality
ID : 17441904200
Organisme : Science and Technology Commission of Shanghai Municipality
ID : 19441909300

Informations de copyright

© 2022 International Center for Artificial Organs and Transplantation and Wiley Periodicals LLC.

Références

Kessler M, Moureau F, Nguyen P. Anticoagulation in chronic hemodialysis: progress toward an optimal approach. Semin Dial. 2015;28:474-89.
Ouseph R, Ward RA. Anticoagulation for intermittent hemodialysis. Semin Dial. 2000;13:181-7.
European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section v. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant. 2002;17(Suppl 7):63-71.
Lazrak HH, Rene E, Elftouh N, Leblanc M, Lafrance JP. Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis. BMC Nephrol. 2017;18:187.
Khwaja A. Kdigo clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179-84.
Liu C, Mao Z, Kang H, Hu J, Zhou F. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Crit Care. 2016;20:144.
Buturovic-Ponikvar J. Is regional citrate anticoagulation the future of hemodialysis? Ther Apher Dial. 2016;20:234-9.
Morgera S, Schneider M, Slowinski T, Vargas-Hein O, Zuckermann-Becker H, Peters H, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med. 2009;37:2018-24.
Schneider AG, Journois D, Rimmele T. Complications of regional citrate anticoagulation: accumulation or overload? Crit Care. 2017;21:281.
van der Voort PH, Postma SR, Kingma WP, Boerma EC, de Heide LJ, Bakker AJ. An observational study on the effects of nadroparin-based and citrate-based continuous venovenous hemofiltration on calcium metabolism. Blood Purif. 2007;25:267-73.
Bianchi NA, Altarelli M, Eckert P, Schneider AG. Complications of regional citrate anticoagulation for continuous renal replacement therapy: an observational study. Blood Purif. 2020;49:567-75.
Garzotto F, Ostermann M, Martin-Langerwerf D, Sanchez-Sanchez M, Teng J, Robert R, et al. The dose response multicentre investigation on fluid assessment (doremifa) in critically ill patients. Crit Care. 2016;20:196.
Zheng Y, Xu Z, Zhu Q, Liu J, Qian J, You H, et al. Citrate pharmacokinetics in critically ill patients with acute kidney injury. PLoS One. 2013;8:e65992.
Yu W, Zhuang F, Ma S, Fan Q, Zhu M, Ding F. Optimized calcium supplementation approach for regional citrate anticoagulation. Nephron. 2019;141:119-27.
Kozik-Jaromin J, Nier V, Heemann U, Kreymann B, Bohler J. Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation. Nephrol Dial Transplant. 2009;24:2244-51.
Jaffrin MY, Ding LH, Laurent JM. Simultaneous convective and diffusive mass transfers in a hemodialyser. J Biomech Eng. 1990;112:212-9.
Schilder L, Nurmohamed SA, ter Wee PM, Paauw NJ, Girbes AR, Beishuizen A, et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrol. 2014;15:19.
Kessler M, Gangemi C, Gutierrez MA, Lacombe JL, Krier-Coudert MJ, Galland R, et al. Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: a prospective proof-of-concept study. Hemodial Int. 2013;17:282-93.
Skagerlind M, Stegmayr BG. An evaluation of four modes of low-dose anticoagulation during intermittent haemodialysis. Eur J Clin Pharmacol. 2018;74:267-74.
Zhang L, Liao Y, Xiang J, Qin W, Wu X, Tang Y, et al. Simplified regional citrate anticoagulation using a calcium-containing replacement solution for continuous venovenous hemofiltration. J Artif Organs. 2013;16:185-92.
Kirwan CJ, Hutchison R, Ghabina S, Schwarze S, Beane A, Ramsay S, et al. Implementation of a simplified regional citrate anticoagulation protocol for post-dilution continuous hemofiltration using a bicarbonate buffered, calcium containing replacement solution. Blood Purif. 2016;42:349-55.
Robert T, Bureau C, Lebourg L, Rondeau E, Petitclerc T, Ridel C. A simple and novel technique for regional citrate anticoagulation during intermittent hemodialysis may obviate the need for calcium monitoring. Intensive Care Med. 2017;43:1927-8.
Strobl K, Hartmann J, Wallner M, Brandl M, Falkenhagen D. A target-oriented algorithm for citrate-calcium anticoagulation in clinical practice. Blood Purif. 2013;36:136-45.
Brandl M, Strobl K, Hartmann J, Kellner K, Posnicek T, Falkenhagen D. A target-orientated algorithm for regional citrate-calcium anticoagulation in extracorporeal therapies. Blood Purif. 2012;33:7-20.

Auteurs

Xiao Bi (X)

Division of Nephrology & Critical Care Nephrology Unit, Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, China.

Qi Zhang (Q)

Division of Nephrology & Critical Care Nephrology Unit, Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, China.

Feng Zhuang (F)

Division of Nephrology & Critical Care Nephrology Unit, Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, China.

Feng Ding (F)

Division of Nephrology & Critical Care Nephrology Unit, Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH